Johnson & Johnson (NYSE:JNJ)

Amazon: The Devil You Know and the Devil You Don’t

The well-established disruption Amazon.com Inc. (NASDAQ: AMZN) has caused in the brick-and-mortar retail business is spreading. And the fear of Amazon is spreading in sectors as varied as real estate ...
Read Full Story »

Merck, DuPont Lead Dow Lower on Tuesday

August 8, 2017: Markets opened lower Tuesday and wobbled near the break-even line for most of the trading session. No significant economic data was released today, but some is on ...
Read Full Story »

Blockbuster Drug Imbruvica Gets Expanded FDA Approval for Chronic Graft Versus Host Disease

A blockbuster drug is about to get a chance to have even higher sales. The U.S. Food and Drug Administration (FDA) has expanded its approval of Imbruvica for the treatment ...
Read Full Story »

GE, Nike Guide DJIA Down on Monday

July 24, 2017: Markets opened mixed Monday as both the Dow and the S&P 500 traded lower late into the afternoon. The financial and tech sectors traded higher Monday while ...
Read Full Story »

Top Analyst Upgrades & Downgrades: American Superconductor, Chipotle, Groupon, J&J, Juniper, Occidental, Wells Fargo and Many More

Stocks have pulled back a tad from all-time highs, and the market indexes were indicated to have a slight drop on Friday morning. Still, indexes remain right at all time ...
Read Full Story »

Why Credit Suisse Prefers Johnson & Johnson Over Pfizer

Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) a close ...
Read Full Story »

Top Analyst Upgrades and Downgrades: BHP Billiton, HP, Kinder Morgan, Marathon Petroleum, Nike, Pfizer, Rite Aid, Tesla and More

Stocks were indicated marginally higher on Thursday after the European Central Bank statement remained quite dovish. The major equity indexes all remain just under all-time highs. Even though this bull ...
Read Full Story »

Johnson & Johnson Shares Slip Following Mixed Earnings

Johnson & Johnson (NYSE: JNJ) released its fiscal second-quarter earnings report before the markets opened on Tuesday. The company posted $1.83 in earnings per share (EPS) on $18.8 billion in ...
Read Full Story »

Goldman Sachs, IBM and More Dow Stocks Reporting Next Week

24/7 Wall St. has put together a preview of the Dow Jones Industrial Average companies scheduled to report their quarterly results this week. Overall, nine Dow components are reporting this ...
Read Full Story »

Goldman Sachs, Wal-Mart Weigh on DJIA Thursday

June 22, 2017: Markets opened slightly higher again Thursday, with all three major indexes turning positive after a short visit into the red and then remaining positive for the rest ...
Read Full Story »

The Top 20 S&P 500 Companies Buying Back Stock in 2017

Long-term investors have generally been a fan of stock buybacks and dividends. After all, dividends can account for about half of all shareholder returns over time. And buybacks can help ...
Read Full Story »

Is the Dow Less Than 1% Away From Its 2017 Peak?

With a Federal Reserve rate hike decision, investors have to keep in mind what to think of the stock market heading into the rest of this summer and what to ...
Read Full Story »

Boeing, 3M Dominate the DJIA Friday

June 2, 2017: Markets opened higher again Friday following a lower-than-expected number from the non-farm payroll report. Bond yields were lower as investors are seeking cover for what looks to ...
Read Full Story »

Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News

When companies see their shares rise almost 50%, most investors probably just assume the news is from a buyout or a merger. In the case of Tuesday's massive gain in ...
Read Full Story »

Why Protagonist Therapeutics Shares Are Climbing

Protagonist Therapeutics Inc. (NASDAQ: PTGX) saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech, a ...
Read Full Story »